🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

After countless talks on provisional stenting, my task @ #EuroPCR2025 is "How to perform optimal DK-Crush" LIVE in-vitro PCI Visible Heart® Laboratories by Rhian E. Davies DO MS Emmanouil Brilakis Join Nieves Gonzalo Maciej Lesiak Tom Johnson FRANCESCO BURZOTTA Gabor G Toth in the Main Arena on May 22, 16:30h PCRonline 🫀

#EuroPCR simultaneous publication! 📕JACC Journals Happy to share our case of concomitant Transcatheter Aortic and Mitral Valve Replacement sciencedirect.com/science/articl… see you in Paris🗼 Julio Echarte José Antonio Baz Manuel Barreiro-Perez Fran Estevez Rocío Glez. Ferreiro miguel piñón Rodrigo Estévez

The #EAPCI educational pathway is coming.. …starting at #ESCcongress 2025! Take your chance to get access to it and become an #EAPCI member: 🔗: escardio.org/Marketing/EAPC… #EuroPCR 2025

Coronary Atherosclerosis Phenotypes in Non-Flow-Limiting Nonculprit Lesions. Focal CAD lesions may be worse than diffuse disease patterns. Presented PCRonline 🫀 #EuroPCR and published simultaneously EuroIntervention #AHAJournals #cardiotwitter @matser89 ahajournals.org/doi/full/10.11…

10-year follow-up of the DANAMI-PRIMULTI trial showed that FFR-guided complete revascularization in STEMI reduced mainly non-culprit lesion revascularizations, with no reduction in MI or death jacc.org/doi/10.1016/j.… JACC Journals EAPCIPresident PCRonline 🫀

What an amazing first day it has been at #EuroPCR. Thank you to all for your enthusiasm and exchange and see you tomorrow for day two

Incidence, evolution and impact of cardiac damage in asymptomatic patients with severe #vhdAS ❤️‍🩹 Interesting analysis of the EARLY TAVR trial by Philippe Genereux #EuroPCR 2025 🇫🇷 Should we redefine the definition of severe #vhdAS?

🔥#EuroPCR 2025 Major Late-Breaking Trials results: Angiography versus physiology-guided PCI in patients undergoing TAVI FAITAVI is the first study comparing FFR-guided PCI with angiography-guided PCI in patients with intermediate CAD and severe symptomatic AS undergoing TAVI,

Great session on multivessel disease in STEMI patient - great discussion on several unsolved issues 🔥Physiology for non-culprit lesion? 🔥Timing of revascularization of non-culprit lesion? 🔥Vulnerable plaques - definition and treatment #EuroPCR Lund University RigsHeart 🫀🚨

🔥#EuroPCR 2025 Major Late-Breaking Trials: Meta-Analysis of Individual Patient Data from the PROTECTED #TAVR and BHF PROTECT-TAVI Trials Despite a clear rationale leading to the development of CEP, this meta-analysis of individual data from these two large RCTs clearly

#EuroPCR 2025 Major Late-Breaking Trials – One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose Results of the 4D-ACS randomised trial show that, at 12-months, NACE occurred in 4.9% of the 1-month #DAPT group and 8.8% of the 12-month DAPT

JUST OUT @ the 20th anniversary PCRonline 🫀 #EuroPCR25 edition of EuroIntervention ! Our expert review on the latest in leaflet modification in #TAVR by my partner Sunny Goel et al eurointervention.pcronline.com/article/leafle… Jaffar Khan DoctorKini George Dangas, MD, MACC, MSCAI Sahil Khera Parasuram Krishnamoorthy MD

#EuroPCR DAY 3️⃣ AGIK + #EAPCI + PCRonline 🫀 Pins loaded MIЯVΛƬ #IC Erik Rafflenbeul Indah Sukmawati, MD Alessandro Beneduce Guillaume Bonnet Hany Ragy Dr Iain Gillingham Carlos Luqueño Mi Chen 陈密

Safety and Efficacy of Cobalt Chromium Everolimus‐Eluting Stents for Treatment of In‐Stent Restenosis: An ILUMIEN IV Substudy | Journal of the American Heart Association ahajournals.org/doi/10.1161/JA…

It’s happening now in Theatre Havane ! #20YearsOfEuroIntervention #EuroPCR ⁦EuroIntervention⁩

Thank you guys. From the bottom of my heart 😘 🙌🏻 Roger Federer Novak Djokovic Andy Murray

Dear Colleagues, dear #PCRCompanions, Thank you for contributing to yet another wonderful edition of #EuroPCR. Whether you were on stage, at the podium, or learning from and exchanging with peers in the room, your participation is what makes this Course so valuable. We truly

Dear Friends and Colleagues, What an incredible week we’ve just shared in Paris at #EuroPCR! Thank you to all attendees for joining us, for your energy, insights, and commitment to learning and improving outcomes for our patients. A special thank you to the faculty, the case

We have a new Lp(a) paper, led by David Erlinge from PROSPECT 2 using IVUS/NIRS. It shows high Lp(a) associates most with vulnerable plaque characteristics, whereas LDL-C with plaque burden. Lp(a) was measured by our UC San Diego Cardiology assay, the only Lp(a) assay I am aware of that is

Our JACC publ from PROSPECT II. ↑ TC, LDL-C, & non-HDL-C were strongly associated with pancoronary athero and lipid deposition. ↑ Lp(a) was strongly associated with focal vulnerable plaques→unique role for Lp(a) role in plaque progression & vulnerability -synergistic with LDL.